Study study type PathologyT1T0Patientssample sizesROB Results

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (all population), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus nab-paclitaxel (ACnp)carboplatine plus nab-paclitaxel (CnP)first-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer and no ALK or EGFR mutations who have not previously received chemotherapy483 / 240some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.400 / 400some concern
inconclusive
  • suggested 24 % decrease in deaths (OS)
  • suggested 39 % decrease in progression or deaths (PFS)
atezolizumab plus carboplatin plus paclitaxel
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus paclitaxel (ACP)bevacizumab and caroplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.402 / 400some concern
inconclusive
    no statistically significant result

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABCP vs BPC WT), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP)bevacizumab and caroplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.356 / 336some concern
conclusif
  • demonstrated 22 % decrease in deaths (OS) (PE)
  • demonstrated 38 % decrease in progression or deaths (PFS) (PE)
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.155 / 129some concern
conclusif
  • demonstrated 49 % decrease in progression or deaths (PFS) (PE)
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (WT), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab (ACnP) plus carboplatine plus nab-paclitaxelcarboplatine plus nab-paclitaxelfirst-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer who have not previously received chemotherapy. (EGFRwt and ALKwt)451 / 228some concern
conclusif
  • demonstrated 21 % decrease in deaths (OS) (PE)
  • demonstrated 36 % decrease in progression or deaths (PFS) (PE)
  • statistically significant 1.4-fold increase in DOR
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin
IMpower-132 (WT) unpublished
 
NCT02657434
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)Atezolizumab (induction and maintenance) plus pemetrexed plus platinepemetrexed plus platineChemotherapy-naive patients with Stage IV non-squamous NSCLC without EGFR or ALK genetic alteration292 / 286NA
conclusif
  • inconclusive 19 % decrease in deaths (OS),deaths (OS) (PE)
  • demonstrated 40 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)
pembrolizumab and pemetrexed plus platin
KEYNOTE-021, 2016
  NCT02039674
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)pembrolizumab with carboplatin plus pemetrexedcarboplatin plus pemetrexedpatients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer60 / 63some concern
conclusif
  • demonstrated 47 % decrease in progression or deaths (PFS) (PE)
  • suggested 46 % decrease in PFS (extension)
  • demonstrated 2.1-fold increase in objective responses (ORR) (PE)
versus placebo plus SoC
pembrolizumab plus SoC
KEYNOTE-189, 2018
  NCT02578680
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)pembrolizumab plus pemetrexed plus platineplacebo plus pemetrexed plus platineparticipants with advanced or metastatic nonsquamous non-small cell lung cancer who have not previously received systemic therapy for advanced disease410 / 206low
conclusif
  • demonstrated 51 % decrease in deaths (OS) (PE)
  • demonstrated 48 % decrease in progression or deaths (PFS) (PE)
  • suggested 44 % decrease in deaths (OS) (extension)
  • suggested 52 % decrease in PFS (extension)
  • more...